3 DOSAGE FORMS & STRENGTHS
Lower doses of vardenafil film-coated tablets should be used as initial therapy in these patients [see Dosage and Administration (2.4)] .Patients taking alpha-blockers who have previously used vardenafil film-coated tablets may change to vardenafil orally disintegrating tablet at the advice of their healthcare provider.
How do these drugs work?
Nitrates: Concomitant use with nitrates in any form is contraindicated [see Contraindications (4.1)] . CYP3A4 Inhibitors: Do not use vardenafil orally disintegrating tablet with strong or moderate CYP3A4 inhibitors such as cobicistat ,ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, atazanavir, clarithromycin and erythromycin [see Warnings and Precautions (5.2) and Drug Interactions (7.2)]. Alpha-Blockers: In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose. [See Warnings and Precautions (5.6) and Drug Interactions (7.1).] A time interval between dosing should be considered when vardenafil orally disintegrating tablet is prescribed concomitantly with alpha-blocker therapy [see Clinical Pharmacology (12.2)]. 4 CONTRAINDICATIONS 4.1 NitratesAdministration of vardenafil orally disintegrating tablet with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see Clinical Pharmacology (12.2)].
Environ. Pollut.
Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors, including vardenafil orally disintegrating tablet, may potentiate the hypotensive effects of nitrates. A suitable time interval following vardenafil orally disintegrating tablet dosing for the safe administration of nitrates online levitra sale or nitric oxide donors has not been determined. Administration of vardenafil orally disintegrating tablet with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see Clinical Pharmacology (12.2)]. 5 WARNINGS AND PRECAUTIONS The evaluation of erectile dysfunction should include a medical assessment, a determination of potential underlying causes and the identification of appropriate treatment.Before prescribing vardenafil orally disintegrating tablet, it is important to note the following:5.1 Cardiovascular EffectsGeneralPhysicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Therefore, treatment for erectile dysfunction, including vardenafil orally disintegrating tablet, should not be used in men for whom sexual activity is not recommended because of their underlying cardiovascular status.There are no controlled clinical data on the safety or efficacy of vardenafil in the following patients; and therefore its use is not recommended until further information is available: unstable angina; hypotension (resting systolic blood pressure of <90 mmHg); uncontrolled hypertension (>170/110 mmHg); recent history of stroke, life-threatening arrhythmia, or myocardial infarction (within the last 6 months); severe cardiac failure.Left Ventricular Outflow ObstructionPatients with left ventricular outflow obstruction (for example, aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators including PDE5 inhibitors.Blood Pressure EffectsVardenafil has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 7 mmHg systolic and 8 mmHg diastolic) [see Clinical Pharmacology (12.2)]. [See Warnings and Precautions (5.6) and Drug Interactions (7.1).
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Levitra Generic | 60mg | 360 + 10 Pills | 906.69€ 863.51€ | |
| Levitra Generic | 60mg | 90 + 6 Pills | 291.82€ 277.92€ | |
| Levitra Original | 20mg | 92 + 4 Pills | 406.22€ 386.88€ | |
| Levitra Generic | 60mg | 60 + 4 Pills | 198.85€ 189.38€ | |
| Levitra Original | 20mg | 22 + 2 Pills | 138.55€ 131.95€ | |
| Levitra Generic | 60mg | 20 Pills | 81.30€ 77.43€ | |
| Levitra Original | 20mg | 4 Pills | 45.87€ 43.69€ | |
| Levitra Professional | 20mg | 10 Pills | 62.37€ 59.40€ | |
| Levitra Soft Tabs | 20mg | 360 + 20 Pills | 682.21€ 649.72€ | |
| Levitra Professional | 20mg | 90 + 2 Pills | 304.49€ 289.99€ | |
| Levitra Generic | 40mg | 10 Pills | 41.37€ 39.40€ | |
| Levitra Original | 20mg | 14 + 2 Pills | 102.27€ 97.40€ | |
| Levitra Generic | 10mg | 120 + 10 Pills | 178.59€ 170.09€ | |
| Levitra Soft Tabs | 20mg | 270 + 10 Pills | 521.78€ 496.93€ |
]A time interval between dosing should be considered when vardenafil orally disintegrating tablet is prescribed concomitantly with alpha-blocker therapy [see Clinical Pharmacology (12.2)].
What is the most important information I should know about vardenafil?
Vardenafil is available in 10 mg orally disintegrating tablets. Vardenafil orally disintegrating tablet should be taken orally, as needed, approximately 60 minutes before sexual activity.
| Precaution/Contraindication | Explanation | Alternatives or Actions |
|---|---|---|
| Use with nitrate medications | Can cause severe hypotension | Consult doctor before use |
| Heart conditions | Risk of cardiovascular events | Medical evaluation recommended |
| Liver or kidney impairment | Affects drug metabolism | Dose adjustment needed |
| Allergies to ingredients | Risk of allergic reactions | Check ingredient list |
Sexual stimulation is required for a response to treatment.
- It is important to follow prescribed dosage instructions.
- Overuse can lead to adverse cardiovascular effects.
- Report any unusual symptoms to your doctor.
Vardenafil orally disintegrating tabletshould be placed on the tongue where it will disintegrate. Those patients who require a lower or higher dose of vardenafil need to be prescribed vardenafil film-coated tablets [see Patient Counseling Information (17)] . Hepatic Impairment: Do not use vardenafil orally disintegrating tabletin patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.3)] . Renal Impairment: Do not use vardenafil orally disintegrating tablet in patients on renal dialysis [see Warnings and Precautions (5.9) and Clinical Pharmacology (12.3)]. Nitrates: Concomitant use with nitrates in any form is contraindicated [see Contraindications (4.1)] . CYP3A4 Inhibitors: Do not use vardenafil orally disintegrating tablet with strong or moderate CYP3A4 inhibitors such as cobicistat ,ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, atazanavir, clarithromycin and erythromycin [see Warnings and Precautions (5.2) and Drug Interactions (7.2)]. Alpha-Blockers: In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose.
About Penile Injection Therapy
[See Warnings and Precautions (5.6) and Drug Interactions (7.1).] A time interval between dosing should be considered when vardenafil orally disintegrating tablet is prescribed concomitantly with alpha-blocker therapy [see Clinical Pharmacology (12.2)].
- Liquid Levitra should be measured with a proper device.
- Avoid mixing with hot liquids to prevent degradation.
- Keep the medication stored at room temperature.
4 CONTRAINDICATIONS 4.1 NitratesAdministration of vardenafil orally disintegrating tablet with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see Clinical Pharmacology (12.2)].
Helping Veterans stay well and well-informed
Lower doses of vardenafil film-coated tablets should be used as initial therapy in these patients [see Dosage and Administration (2.4)] .Patients taking alpha-blockers who have previously used vardenafil film-coated tablets may change to vardenafil orally disintegrating tablet at the advice of their healthcare provider. [See Warnings and Precautions (5.6) and Drug Interactions (7.1). ]A time interval between dosing should be considered when vardenafil orally disintegrating tablet is prescribed concomitantly with alpha-blocker therapy [see Clinical Pharmacology (12.2)]. Vardenafil is available in 10 mg orally disintegrating tablets. Vardenafil orally disintegrating tablet should be taken orally, as needed, approximately 60 minutes before sexual activity.
Multi-Interface polarization engineering constructed 1T-2H MoS2 QDs/Y-NaBi(MoO4)2 multiple heterostructure for high-efficient piezoelectric-photoelectrocatalysis PDE-5i degradation
Sexual stimulation is required for a response to treatment. Vardenafil orally disintegrating tabletshould be placed on the tongue where it will disintegrate. Those patients who require a lower or higher dose of vardenafil need to be prescribed vardenafil film-coated tablets [see Patient Counseling Information (17)] . Hepatic Impairment: Do not use vardenafil orally disintegrating tabletin patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.3)] . Renal Impairment: Do not use vardenafil orally disintegrating tablet in patients on renal dialysis [see Warnings and Precautions (5.9) and Clinical Pharmacology (12.3)]. Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors, including vardenafil orally disintegrating tablet, may potentiate the hypotensive effects of nitrates. A suitable time interval following vardenafil orally disintegrating tablet dosing for the safe administration of nitrates online levitra sale or nitric oxide donors has not been determined. Administration of vardenafil orally disintegrating tablet with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see Clinical Pharmacology (12.2)]. 5 WARNINGS AND PRECAUTIONS The evaluation of erectile dysfunction should include a medical assessment, a determination of potential underlying causes and the identification of appropriate treatment.Before prescribing vardenafil orally disintegrating tablet, it is important to note the following:5.1 Cardiovascular EffectsGeneralPhysicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity.
| Advantage | Explanation | Compared to Tablets |
|---|---|---|
| Quick Absorption | Liquid form is absorbed faster than tablets | Faster onset |
| Easier to Swallow | Suitable for individuals with swallowing difficulties | Better for some users |
| Dose Flexibility | Can be measured precisely | More adaptable dosing |
| Faster Effects | Effects seen sooner after intake | More immediate results |
Therefore, treatment for erectile dysfunction, including vardenafil orally disintegrating tablet, should not be used in men for whom sexual activity is not recommended because of their underlying cardiovascular status.There are no controlled clinical data on the safety or efficacy of vardenafil in the following patients; and therefore its use is not recommended until further information is available: unstable angina; hypotension (resting systolic blood pressure of <90 mmHg); uncontrolled hypertension (>170/110 mmHg); recent history of stroke, life-threatening arrhythmia, or myocardial infarction (within the last 6 months); severe cardiac failure.Left Ventricular Outflow ObstructionPatients with left ventricular outflow obstruction (for example, aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators including PDE5 inhibitors.Blood Pressure EffectsVardenafil has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 7 mmHg systolic and 8 mmHg diastolic) [see Clinical Pharmacology (12.2)]. While this normally would be expected to be of little consequence in most patients, prior to prescribing vardenafil orally disintegrating tablet, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects.5.2 Potential for Drug Interactions with Strong or Moderate CYP3A4 InhibitorsConcomitant administration with strong CYP3A4 inhibitors (such as ritonavir, indinavir, ketoconazole and cobicistat) or moderate CYP3A4 inhibitors (such as erythromycin) increases plasma concentrations of vardenafil. Do not use vardenafil orally disintegrating tablet in patients taking strong or moderate CYP3A4 inhibitors.
| Dosage | Frequency | Onset Time | Duration of Effect | Notes |
|---|---|---|---|---|
| 10 mL (200 mg) | Once 30 minutes before | 30-60 min | Up to 4 hours | Maximum recommended dose |
| 5 mL (100 mg) | As needed | 30 min | 3-4 hours | Consult doctor for tailored dose |
| 15 mL (300 mg) | 24 hours apart | 30-60 min | Up to 4 hours | Do not exceed recommended dose |
[See Dosage and Administration (2.4), Drug Interactions (7.2) and Patient Counseling Information (17). ]5.3 Risk of PriapismThere have been rare reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds, including vardenafil. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result.Vardenafil orally disintegrating tablet should be used with caution by patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) or by patients who have conditions that may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).5.4 Effects on the EyePhysicians should advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including vardenafil orally disintegrating tablet, and seek medical attention in the event of sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision, including permanent loss of vision, that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors. Based on published literature, the annual incidence of NAION is 2.5–11.8 cases per 100,000 in males aged ≥50.An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Neither the rare postmarketing reports, nor the association of PDE5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE5 inhibitor use and NAION [see Adverse Reactions (6.2)].Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Individuals who have already experienced NAION are at increased risk of NAION recurrence.Therefore, PDE5 inhibitors, including vardenafil orally disintegrating tablet, should be used with caution in these patients and only when the anticipated benefits outweigh the risks.
- Liquid Levitra offers an alternative to pills for convenience.
- It is primarily used to treat erectile dysfunction.
- Suitable for those with difficulty swallowing tablets.
Individuals with “crowded” optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including vardenafil orally disintegrating tablet, for this uncommon condition.Vardenafil orally disintegrating tablet has not been evaluated in patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, therefore its use is not recommended until further information is available in those patients.5.5 Sudden Hearing LossPhysicians should advise patients to stop taking all PDE5 inhibitors, including vardenafil orally disintegrating tablet, and seek prompt medical attention in the event of sudden decrease or loss of hearing.
What is the risk associated with Levitra?
It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)].5.6 Alpha-BlockersIn patients taking alpha-blockers, do not initiate vardenafil therapy with vardenafil orally disintegrating tablet.
Adverse Effects
While this normally would be expected to be of little consequence in most patients, prior to prescribing vardenafil orally disintegrating tablet, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects.5.2 Potential for Drug Interactions with Strong or Moderate CYP3A4 InhibitorsConcomitant administration with strong CYP3A4 inhibitors (such as ritonavir, indinavir, ketoconazole and cobicistat) or moderate CYP3A4 inhibitors (such as erythromycin) increases plasma concentrations of vardenafil. Do not use vardenafil orally disintegrating tablet in patients taking strong or moderate CYP3A4 inhibitors. [See Dosage and Administration (2.4), Drug Interactions (7.2) and Patient Counseling Information (17). ]5.3 Risk of PriapismThere have been rare reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds, including vardenafil. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result.Vardenafil orally disintegrating tablet should be used with caution by patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) or by patients who have conditions that may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).5.4 Effects on the EyePhysicians should advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including vardenafil orally disintegrating tablet, and seek medical attention in the event of sudden loss of vision in one or both eyes.
ED Prescriptions for $1-2 Per Pill
Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision, including permanent loss of vision, that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors. Based on published literature, the annual incidence of NAION is 2.5–11.8 cases per 100,000 in males aged ≥50.An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Neither the rare postmarketing reports, nor the association of PDE5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE5 inhibitor use and NAION [see Adverse Reactions (6.2)].Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Patients treated with alpha-blockers who have previously used vardenafil film-coated tablets may be changed to vardenafil orally disintegrating tablet at the advice of their healthcare provider. Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. PDE5 inhibitors, including vardenafil orally disintegrating tablet, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly [see Drug Interactions (7.1) and Clinical Pharmacology (12.2)] leading to symptomatic hypotension (for example, fainting). Consideration should be given to the following:Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor.
What are the differences between vardenafil and tadalafil?
Individuals who have already experienced NAION are at increased risk of NAION recurrence.Therefore, PDE5 inhibitors, including vardenafil orally disintegrating tablet, should be used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with “crowded” optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including vardenafil orally disintegrating tablet, for this uncommon condition.Vardenafil orally disintegrating tablet has not been evaluated in patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, therefore its use is not recommended until further information is available in those patients.5.5 Sudden Hearing LossPhysicians should advise patients to stop taking all PDE5 inhibitors, including vardenafil orally disintegrating tablet, and seek prompt medical attention in the event of sudden decrease or loss of hearing. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)].5.6 Alpha-BlockersIn patients taking alpha-blockers, do not initiate vardenafil therapy with vardenafil orally disintegrating tablet. Patients treated with alpha-blockers who have previously used vardenafil film-coated tablets may be changed to vardenafil orally disintegrating tablet at the advice of their healthcare provider. Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.
Sample preparation
PDE5 inhibitors, including vardenafil orally disintegrating tablet, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly [see Drug Interactions (7.1) and Clinical Pharmacology (12.2)] leading to symptomatic hypotension (for example, fainting). Consideration should be given to the following:Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose. Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose.
- Patient Experiences with Levitra Treatment
- Proper Dosage and Administration Instructions
- How Often Should Kids Eat Fast Food?
- 10 OVERDOSAGE
- To Purchase Kamagra Oral Jelly Without Prescription Visit Our Pharmacy ↓
- GoSpring Ratgeber: Levitra®
- Seguridad, receta y verificación — Comprar cialis farmacia españa